Lipoprotein(a) as a blood marker for large artery atherosclerosis stroke etiology: validation in a prospective cohort from a swiss stroke center

CONCLUSIONS: In a well-characterised cohort of patients with ischaemic stroke, we validated the association of higher Lp(a) levels with LAA stroke aetiology, independent of traditional cardiovascular risk factors. These findings may inform randomised clinical trials investigating the effect of Lp(a) lowering agents on cardiovascular outcomes. The CoRisk (CoPeptin for Risk Stratification in Acute Patients) study is registered on ClinicalTrials.gov.REGISTRATION NUMBER: NCT00878813.PMID:38579294 | DOI:10.57187/s.3633

Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Salome Rudin Lilian Kriemler Tolga D Dittrich Annaelle Zietz Juliane Schweizer Markus Arnold Nils Peters Filip Barinka Simon Jung Marcel Arnold Urs Fischer Katharina Rentsch Mirjam Christ-Crain Mira Katan Gian Marco De Marchis Source Type: research